248 related articles for article (PubMed ID: 26205342)
1. Resveratrol and derivatives for the treatment of atrial fibrillation.
Baczkó I; Light PE
Ann N Y Acad Sci; 2015 Aug; 1348(1):68-74. PubMed ID: 26205342
[TBL] [Abstract][Full Text] [Related]
2. Red Wine, Resveratrol and Atrial Fibrillation.
Stephan LS; Almeida ED; Markoski MM; Garavaglia J; Marcadenti A
Nutrients; 2017 Oct; 9(11):. PubMed ID: 29084143
[TBL] [Abstract][Full Text] [Related]
3. In vitro electrophysiological mechanisms for antiarrhythmic efficacy of resveratrol, a red wine antioxidant.
Chen WP; Su MJ; Hung LM
Eur J Pharmacol; 2007 Jan; 554(2-3):196-204. PubMed ID: 17107672
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation.
Chong E; Chang SL; Hsiao YW; Singhal R; Liu SH; Leha T; Lin WY; Hsu CP; Chen YC; Chen YJ; Wu TJ; Higa S; Chen SA
Heart Rhythm; 2015 May; 12(5):1046-56. PubMed ID: 25640634
[TBL] [Abstract][Full Text] [Related]
5. New directions in antiarrhythmic drug therapy for atrial fibrillation.
Heijman J; Voigt N; Dobrev D
Future Cardiol; 2013 Jan; 9(1):71-88. PubMed ID: 23259476
[TBL] [Abstract][Full Text] [Related]
6. Novel pharmacological therapies for atrial fibrillation.
Bagwe S; Leonardi M; Bissett J
Curr Opin Cardiol; 2007 Sep; 22(5):450-7. PubMed ID: 17762547
[TBL] [Abstract][Full Text] [Related]
7. Electropharmacological effects of antiarrhythmic drugs on atrial fibrillation termination. Part I: Molecular and ionic fundamentals of antiarrhythmic drug actions.
Calò L; Sciarra L; Lamberti F; Loricchio ML; Castro A; Bianconi L; Pandozi C; Gaita F; Santini M
Ital Heart J; 2003 Jul; 4(7):430-41. PubMed ID: 14558293
[TBL] [Abstract][Full Text] [Related]
8. New antiarrhythmic agents for atrial fibrillation and atrial flutter.
Pecini R; Elming H; Pedersen OD; Torp-Pedersen C
Expert Opin Emerg Drugs; 2005 May; 10(2):311-22. PubMed ID: 15934869
[TBL] [Abstract][Full Text] [Related]
9. [Restoration and maintenance of sinus rhythm in patients with atrial fibrillation. New pharmacological approaches].
Runge S; Dietz R; Haverkamp W
Dtsch Med Wochenschr; 2008 Dec; 133(49):2572-8. PubMed ID: 19039713
[TBL] [Abstract][Full Text] [Related]
10. An overview of the efficacy of resveratrol in the management of ischemic heart disease.
Raj P; Zieroth S; Netticadan T
Ann N Y Acad Sci; 2015 Aug; 1348(1):55-67. PubMed ID: 26227659
[TBL] [Abstract][Full Text] [Related]
11. New pharmacological approaches to atrial fibrillation.
Milnes JT; Madge DJ; Ford JW
Drug Discov Today; 2012 Jul; 17(13-14):654-9. PubMed ID: 22370250
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective and antiarrhythmic effects of resveratrol--a modern perspective on an old treatment: editorial to "resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction" by Chen et al.
Liew R
Cardiovasc Drugs Ther; 2008 Dec; 22(6):427-8. PubMed ID: 18949544
[No Abstract] [Full Text] [Related]
13. Acute electrophysiologic effects of the polyphenols resveratrol and piceatannol in rabbit atria.
Frommeyer G; Wolfes J; Ellermann C; Kochhäuser S; Dechering DG; Eckardt L
Clin Exp Pharmacol Physiol; 2019 Jan; 46(1):94-98. PubMed ID: 29956844
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy for atrial arrhythmias: present and future.
Mazzini MJ; Monahan KM
Heart Rhythm; 2008 Jun; 5(6 Suppl):S26-31. PubMed ID: 18456197
[TBL] [Abstract][Full Text] [Related]
15. Antifibrillatory agents and potassium channels in the atria: pore block versus channel trafficking.
McEwen DP; Martens JR
Mol Interv; 2009 Apr; 9(2):79-86. PubMed ID: 19401540
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications.
Fragakis N; Koskinas KC; Vassilikos V
Pacing Clin Electrophysiol; 2014 Oct; 37(10):1412-20. PubMed ID: 25138058
[TBL] [Abstract][Full Text] [Related]
17. New pharmacological targets and treatments for atrial fibrillation.
Carlsson L; Duker G; Jacobson I
Trends Pharmacol Sci; 2010 Aug; 31(8):364-71. PubMed ID: 20605645
[TBL] [Abstract][Full Text] [Related]
18. Vernakalant hydrochloride for the treatment of atrial fibrillation.
Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
[TBL] [Abstract][Full Text] [Related]
19. Cardiac ion channels and mechanisms for protection against atrial fibrillation.
Grunnet M; Bentzen BH; Sørensen US; Diness JG
Rev Physiol Biochem Pharmacol; 2012; 162():1-58. PubMed ID: 21987061
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol in cardiovascular health and disease.
Petrovski G; Gurusamy N; Das DK
Ann N Y Acad Sci; 2011 Jan; 1215():22-33. PubMed ID: 21261638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
